Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems Inc. (NYSE: INSP) provides innovative neurostimulation solutions for obstructive sleep apnea (OSA) treatment. This news hub offers investors and healthcare professionals centralized access to official updates, including FDA milestones, clinical trial results, and strategic developments.
Track the company’s progress in advancing minimally invasive therapies through verified press releases, regulatory filings, and market expansion announcements. Key updates include earnings reports, partnership agreements, and advancements in OSA treatment technology.
Discover how Inspire Medical maintains compliance with global medical device standards while delivering clinically validated solutions. Content is organized chronologically for efficient research, with clear sourcing to ensure reliability.
Bookmark this page for real-time updates on INSP’s neurostimulation innovations and their impact on sleep medicine. For comprehensive analysis, combine these primary sources with third-party market commentary available across Stock Titan.
Inspire Medical Systems (NYSE:INSP) reported mixed Q2 2025 financial results, with revenue growing 11% year-over-year to $217.1 million. The company posted a net loss of $3.6 million, or $0.12 per share, compared to net income of $9.8 million in Q2 2024. Adjusted net income was $13.3 million ($0.45 per share).
The company launched its next-generation Inspire V neurostimulation system in the U.S., though the rollout is progressing slower than anticipated. Due to these operational challenges, INSP revised its full-year 2025 guidance downward, now expecting revenue of $900-910 million (previously $940-955 million) and diluted EPS of $0.40-0.50 (down from $2.20-2.30).
Additionally, Randy Ban, Executive VP of Patient Access and Therapy Development, announced his retirement effective January 30, 2026.
Inspire Medical Systems (NYSE: INSP) has scheduled its second quarter 2025 financial results release for August 4, 2025 after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss financial performance and business updates.
Investors can access the earnings call through two methods: a webcast via the company's Investor Relations website for those planning to listen only, or a separate registration link for those intending to ask questions. The company recommends registering at least 10 minutes before the call. A replay will be available on the Investor Relations website approximately two hours after the event and will be archived for two weeks.
Inspire Medical Systems (NYSE: INSP), a pioneer in obstructive sleep apnea medical technology, has announced its upcoming participation in the BofA Securities 2025 Health Care Conference.
The company's management team is scheduled to deliver their presentation on Tuesday, May 13, 2025, at 2:20 p.m. Eastern Time. Investors and interested parties can access the presentation through a live webcast.
Key Details:
- Event: BofA Securities 2025 Health Care Conference
- Date: May 13, 2025
- Time: 2:20 p.m. ET
- Access: Live webcast available
- Replay: Available for two weeks post-presentation in the Event Archive section of Inspire's Investor website
Inspire Medical Systems (NYSE: INSP) has announced the appointment of two leading physicians as Vice President, Senior Medical Directors. Dr. Paul T. Hoff, an otolaryngologist, and Dr. Ruchir P. Patel, a sleep medicine specialist, will join the company effective April 21 and June 2, respectively.
Dr. Hoff, an Associate Professor at the University of Michigan with over 25 years of clinical practice, has served as President of both the Michigan Otolaryngology Society and International Surgical Sleep Society. Dr. Patel, founder of The Insomnia and Sleep Institute of Arizona, brings 15 years of clinical experience and expertise in sleep disorders medicine.
Both physicians will maintain their independent clinical practices while contributing to Inspire's medical education, training, and future technology developments for obstructive sleep apnea (OSA) treatment solutions.
Inspire Medical Systems (NYSE: INSP) has scheduled its first quarter 2025 financial results release for Monday, May 5, 2025, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss the quarterly results and recent business developments.
The earnings call will be accessible through two options: a webcast via the company's Investor Relations page for listeners, and a separate registration link for participants planning to ask questions. Participants are advised to register at least 10 minutes before the call. A replay will be available on the Investor Relations website approximately two hours after the event and will be archived for two weeks.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its upcoming participation at the KeyBanc Capital Markets Healthcare Forum.
The company's management team is scheduled to deliver their presentation on Tuesday, March 18, 2025, at 3:00 p.m. Eastern Time. Investors and interested parties can access the presentation through a live webcast, with a replay available for two weeks afterward in the Event Archive section of Inspire's Investor website at investors.inspiresleep.com.
Inspire Medical Systems (NYSE: INSP) reported strong Q4 2024 financial results with revenue reaching $239.7 million, up 25% year-over-year, and full-year revenue of $802.8 million, a 28% increase from 2023. The company achieved a gross margin of 85.0% in Q4 2024 and reported net income of $35.2 million with diluted EPS of $1.15.
Key operational highlights include the activation of 72 new U.S. centers, bringing the total to 1,435 medical centers, and the creation of 12 new sales territories, totaling 335 in the U.S. Operating cash flow for 2024 reached $130.2 million. The company initiated a $75 million accelerated share repurchase program and surpassed 90,000 patients treated with Inspire therapy.
For 2025, Inspire reaffirms revenue guidance of $940-955 million (17-19% growth) and introduces diluted EPS guidance of $2.10-2.20.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
